AbbVie reported better-than-expected Q4 results with non-GAAP EPS of $2.71 and a 10% revenue increase year-over-year, driven by strong sales of Skyrizi and Rinvoq offsetting declines in Humira. The company projects adjusted EPS of $14.37–$14.57 for fiscal year 2026 and expects robust free cash flow of $18.5 billion, supporting its high dividend yield. Despite an 8% year-to-date stock decline and recent sector weakness, AbbVie's valuation, forward EPS growth, and technical support near $200 underpin a bullish outlook. Analysts maintain a 'Buy' rating based on these fundamentals and a 5% free cash flow yield.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
